6LXY image
Entry Detail
PDB ID:
6LXY
Title:
IRAK4 in complex with inhibitor
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-02-12
Release Date:
2020-11-25
Method Details:
Experimental Method:
Resolution:
2.19 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Interleukin-1 receptor-associated kinase 4
Chain IDs:A, B, C (auth: D), D (auth: E)
Chain Length:305
Number of Molecules:4
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP A SER modified residue
TPO A THR modified residue
Primary Citation

Abstact

IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21, which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures